EN DE
Watch Simris Alg AB (publ) for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Simris Alg AB (publ) (SIMRIS-B) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Simris Alg AB (publ) stock SEK 0.05, price SEK 0.10, that is 49.4% below the price, quality 12 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0008091664

SA Simris Alg AB (publ) logo Thin data Nov 11, 2026

Simris Alg AB (publ)

SIMRIS-B · ST
Weakest Setup

Our calculation puts a fair price 49% below what the stock costs today.

Negative equity (buybacks among others)
Revenue last quarter 72% below a year ago.
Fair value kr 0.0481 · Strongly overvalued
Quality 12/100
Weak Growth (revenue 5y −5.7 %/yr in SEK)
Negative free cash flow
Trails peers (1/4)
Narrow moat 16/100 · thin data
Thin data
Estimate
Watch Simris Alg AB (publ) for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 0.1350 kr 0.0800 Fair Value kr 0.0481 May 2026 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

5‑month range kr 0.0800 – kr 0.1350 · fair‑value band kr 0.0360 – kr 0.0601 · the kr 0.0950 price screens above the kr 0.0481 fair value. As of Nov 11, 2026.

Follow Simris Alg AB (publ) in your weekly email

Every Wednesday you see whether Simris Alg AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria.

Show moreShow less

It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammenhög, Sweden.

Stock analysis

Simris Alg AB (publ) (SIMRIS-B) currently trades at kr 0.0950, while our estimate is kr 0.0481, 49% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.0360 (bear) to kr 0.0601 (bull), the price of kr 0.0950 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 12/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Simris Alg AB (publ) reported revenue of 1.6M SEK in FY2025 versus 6.1M SEK in FY2021, a compound −28.4%/yr. Reported net income was −26.8M SEK in FY2025.

Key figures

Market cap 153M SEK (≈ $15.4M) Micro · EPS (TTM) kr −0.0300 · Return on equity −1,223% · Return on assets (EBIT) −35.3% (5-year average) · Operating margin −2,774% · Revenue (TTM) 1.4M SEK · Revenue growth (YoY) −71.5% · Free cash flow −16.0M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −49%, SIMRIS-B screens richer than that median.

Fair Value

Bear kr 0.0360 Fair Value kr 0.0481 Bull kr 0.0601
Price kr 0.0950 · Downside -49.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 12/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 1
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 68
How calm the share price moves, does not count
Near the 52-week high 35
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−44.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.7%
Start year 2020 (pandemic). Over 10 years: +19.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,093.9% (2020) → −1,940.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SIMRIS-B screens overvalued: fair value 49% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Simris Alg AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 12 · Bottom 25%
Fair Value upside −49.4% · Bottom 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −18.1% · Above median
Growth and dividend
Revenue growth (quarter YoY) −71.5% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $959.41 $1,275 +33% vs SIMRIS-B
Vertex Pharmaceuticals Incorporated VRTX $547.03 $602.68 +10% vs SIMRIS-B
Samsung Biologics Co 207940 1,430,000 KRW 1,573,000 KRW +10% vs SIMRIS-B
Genmab A/S GMAB kr 3,561 kr 3,880 +9% vs SIMRIS-B
argenx SE ARGX $977.58 $908.40 −7% vs SIMRIS-B
CSL Limited CSL A$204.54 A$181.40 −11% vs SIMRIS-B
Moderna, Inc MRNA $248.69 $158.70 −36% vs SIMRIS-B
BeOne Medicines AG 6160 HK$251.80 HK$152.80 −39% vs SIMRIS-B
Celltrion, Inc 068270 207,000 KRW 74,945 KRW −64% vs SIMRIS-B
Royalty Pharma plc RPRX $70.01 $19.01 −73% vs SIMRIS-B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Simris Alg AB (publ): fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Simris Alg AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/SIMRIS-B

Frequently asked questions

Is Simris Alg AB (publ) (SIMRIS-B) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is kr 0.0481 versus a price of kr 0.0950, about 49% lower (overvalued).
What is the fair value of SIMRIS-B?
Our estimate for Simris Alg AB (publ) is kr 0.0481 (as of Nov 11, 2026), built from audited fundamentals. The current price: kr 0.0950.
What is the quality score of SIMRIS-B?
Simris Alg AB (publ) has a Quality Score of 12/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Simris Alg AB (publ) (SIMRIS-B)?
Our calculated price target is the estimate of kr 0.0481 (as of Nov 11, 2026). Cautious scenario kr 0.0360, optimistic scenario kr 0.0601. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Simris Alg AB (publ) stock forecast for 2026?
Our estimate puts fair value at kr 0.0481, about 49% lower versus a price of kr 0.0950 (overvalued). Cautious scenario kr 0.0360, optimistic scenario kr 0.0601. The calculation is refreshed regularly with new filings.
What is the revenue of Simris Alg AB (publ) (SIMRIS-B)?
Simris Alg AB (publ) reported trailing-twelve-month revenue of about 1.4M SEK (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Simris Alg AB (publ) (SIMRIS-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Simris Alg AB (publ) it is kr 0.0481 per share (as of Nov 11, 2026), against a price of kr 0.0950.
Is Simris Alg AB (publ) stock overvalued or undervalued in 2026?
As of Nov 11, 2026, SIMRIS-B trades above its calculated fair value: price kr 0.0950, fair value kr 0.0481, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SIMRIS-B?
No. The price is what the market pays today (kr 0.0950); the fair value is what the company's own numbers justify (kr 0.0481). For Simris Alg AB (publ) the two are kr 0.0469 per share apart. That gap is exactly why we show both numbers side by side.
How much is Simris Alg AB (publ) worth?
The market values Simris Alg AB (publ) at about 153M SEK (market capitalisation, as of Nov 11, 2026). Per share that is kr 0.0950; our models calculate a fair value of kr 0.0481 per share.
What do the bullish and bearish scenarios say about SIMRIS-B?
Our models span a range for Simris Alg AB (publ): cautious scenario kr 0.0360, base kr 0.0481, optimistic kr 0.0601 per share (as of Nov 11, 2026, price kr 0.0950). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Simris Alg AB (publ) (SIMRIS-B)?
Balance-sheet figures for Simris Alg AB (publ) (as of Nov 11, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 12/100, which measures business quality independently of the share price.
Which stocks are comparable to Simris Alg AB (publ)?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Simris Alg AB (publ) stock attractive at the current price?
The data as of Nov 11, 2026: price kr 0.0950, calculated fair value kr 0.0481 (−49%), Quality Score 12/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Simris Alg AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Simris Alg AB (publ) (SIMRIS-B)?
The closing price on Nov 11, 2026 was kr 0.0950. Our estimate is kr 0.0481, about 49% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Simris Alg AB (publ) right now?
The price sits above even our optimistic bull case (kr 0.0601). The favourable scenario is already priced in. Weak quality (12/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Simris Alg AB (publ)

How large is the market capitalisation of Simris Alg AB (publ) (SIMRIS-B)?
The market capitalisation of Simris Alg AB (publ) is 153M SEK (≈ $15.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Simris Alg AB (publ) (SIMRIS-B)?
Earnings per share at Simris Alg AB (publ) are kr −0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Simris Alg AB (publ) (SIMRIS-B)?
The return on equity (ROE) of Simris Alg AB (publ) is −1,223% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Simris Alg AB (publ) (SIMRIS-B)?
On an EBIT basis the return on assets of Simris Alg AB (publ) is −35.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Simris Alg AB (publ) (SIMRIS-B)?
The operating margin of Simris Alg AB (publ) is −2,774% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Simris Alg AB (publ) (SIMRIS-B)?
Revenue at Simris Alg AB (publ) is growing −71.5% versus a year earlier (3y avg −26.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Simris Alg AB (publ) (SIMRIS-B) generate?
The free cash flow of Simris Alg AB (publ) is −16.0M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Simris Alg AB (publ) (SIMRIS-B) carry?
The net debt of Simris Alg AB (publ) is 86.2M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Simris Alg AB (publ) in the live analysis

One click puts Simris Alg AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.